[1] 赫捷, 陈万青. 中国肿瘤登记年报(2012). 军事医学科学出版社. 北京, 2012:27- 60.
[2] Yang S, Luo C, Gu Q, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.Oncotarget, 2016, 2: 5461-5469.
[3] 程兮,邱伟华. 肝癌合并门静脉癌栓的多学科治疗进展.外科理论与实践, 2015, 20: 201-204.
[4] Mohamad B, Shah V, Onyshchenko M,et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int, 2016, 10: 632-639.
[5] Yopp AC, Choti MA. Non-alcoholic steatohepatitis-related hepatocellular carcinoma: A growing epidemic? Dig Dis, 2015, 33: 642-647.
[6] Homey B,Muller A,Zlotnik A.Chemokines:agents for the immuno-therapy of cancer? Nat Rev Immunol,2002, 2: 175-184.
[7] Ruckes T,Saul D,Van Snick J,et a1.Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309.Blood,2001, 98: 1150-1159.
[8] Zhou SL , Dai Z , Zhou ZJ , et al . Overex pression of CXCL5 mediates neut rophil infilt ration and indicates poo r prognosis for hepatocellular carcinoma.Hepatology,2012,56:2242-2254.
[9] Sutton A, Friand V, Brulé-Donneger S, et al. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res, 2007, 5: 21-33.
[10] Liu X, Jing X, Cheng X, et al. FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation. Med Oncol, 2016, 33: 46.
[11] Tian H, Huang P, Zhao Z, et al. HIF-1alpha plays a role in the chemotacticmig ration of hepatocarcinoma cells through the modulation of CXCL6 expression. Cell Physiol Biochem, 2014, 34: 1536-1546 .
[12] Liu H, Pan Z, Li A, et al. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol, 2008, 5: 373-378.
[13] Nagamine T, Hayakawa K, Kusakabe T, et al. Inhibitory effect of fucoidan on Huh7 hepatoma cells through down regulation of CXCL12. Nutr Cancer, 2009, 61: 340-347.
[14] Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis, 2014, 23: e1488.
[15] Zhang R, Pan X, Huang Z, et al. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One, 2011, 6: e23831.
[16] Li W, Gomez E, Zhang Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res, 2007, 26: 527-533.
[17] Tang L, Hu HD, Hu P, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther, 2007,14:1226-1234. |
